talquetamab (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Multiple Myeloma

Pending FDA approval for relapsed or refractory multiple myeloma



Mechanism of Action

Bispecific humanized monoclonal antibody against CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen, with potential antineoplastic activity

Upon administration, talquetamab binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells, which results in cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte response against GPRC5D-expressing tumor cells

GPRC5D is overexpressed on certain tumors (eg, multiple myeloma), while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation



No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.